High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysisAlexander Greb, Andreas Engert, Julia Bohlius et al.|Cancer Treatment Reviews|2007Cited by 86
Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphomaKitsada Wudhikarn, Udomsak Bunworasate, Jakrawadee Julamanee et al.|Hematological Oncology|2019Cited by 13
Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study GroupKitsada Wudhikarn, Tanin Intragumtornchai, Supachai Ekwattanakit et al.|Journal of Geriatric Oncology|2019Cited by 7
Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registryTanin Intragumtornchai, Kitsada Wudhikarn, Udomsak Bunworasate et al.|Annals of Hematology|2016Cited by 6
Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study GroupKitsada Wudhikarn, Tanin Intragumtornchai, Udomsak Bunworasate et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 2